Trauma to the joint is an obvious cause of stiffness and pain, so if youve suffered a recent accident or injury, theres a good chance resulting TMJ is temporary and will fade as you heal
Mechanism of Action Tirzepatide: Dual incretin (GIP + GLP-1) enhanced metabolic impact Wegovy: GLP-1 receptor agonist now with higher receptor engagement Weight Loss Outcomes Tirzepatide: ~22% weight reduction in trials Wegovy 7.2 mg: ~2021% weight reduction The efficacy gap is narrowing significantly Cardiometabolic Profile Wegovy: Strong, established cardiovascular outcome data Tirzepatide: Superior glycemic control and insulin sensitivity Safety & Tolerability Both therapies show dose-dependent GI side effects Overall safety profiles remain comparable The Big Picture We are witnessing a shift from: Single-hormone optimization (high-dose semaglutide) to Multi-hormone targeting (tirzepatide) Conclusion While Wegovy is rapidly closing the efficacy gap with dose escalation, Tirzepatide continues to lead as a next-generation metabolic therapy
these changes do not make it a growth-hormone secretagogue, instead they sharply reduce its binding to IGF-binding proteins (IGFBPs), which is what extends its circulating half-life and potency relative to native IGF-1
At standard dosing, a 70mg vial lasts approximately 30 days
Does AOD-9604 help with exercise recovery
But convenience means nothing if the dosing is wrong
